U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16ClNO3.ClH
Molecular Weight 294.174
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MECLOFENOXATE HYDROCHLORIDE

SMILES

Cl.CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1

InChI

InChIKey=FIVHOHCAXWQPGC-UHFFFAOYSA-N
InChI=1S/C12H16ClNO3.ClH/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11;/h3-6H,7-9H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula C12H16ClNO3
Molecular Weight 257.713
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://toppharma.co.uk/top-pharma-product/powder-for-injection/meclofenoxate/

Meclofenoxate (INN, BAN) (brand name Lucidril), also known as centrophenoxine, is a cholinergic nootropic used as a dietary supplement and drug in the treatment of symptoms of senile dementia and Alzheimer's disease. Meclofenoxate has been shown in studies to be effective in enhancing the memory and in improving the cognitive functions of the elderly. Some studies even suggest that Meclofenoxate has the ability to reverse the signs of brain aging. While claims about its ability as a nootropic agent have not been fully established in clinical trials, some studies do strongly suggest that it is indeed very effective in improving memory retention and recall. Meclofenoxate HCL Powder for Injection is also indicated for the following conditions: comma; skull and brain trauma; following a stroke; encephalopathy; mental disorders (in combination with psychotropic agents); mental and psychomotor retardation in children; brain intoxication; alcohol psychoses; neuritis and polyneuritis. The main mechanism of action of Meclofenoxate is generally believed to be cholinergic in nature. As an efficient transporter of DMAE, Meclofenoxate encourages the production of choline in the brain, which is then synthesized into acetylcholine. The more acetylcholine neurotransmitters in the brain, the better and more efficient the cognitive functions will be. Meclofenoxate also increases cellular membrane phospholipids

CNS Activity

Curator's Comment: Meclofenoxate increases the dimethylethanolamine or DMAE levels in the brain. DMAE is a precursor of acetylcholine, an important neurotransmitter in the brain believed to be responsible for most of the cognitive processes within it.

Approval Year

Conditions

Conditions

PubMed

PubMed

TitleDatePubMed
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?
2001 Feb
Cholinergic medication for neuroleptic-induced tardive dyskinesia.
2002
Pharmacological interventions against aging through the cell plasma membrane: a review of the experimental results obtained in animals and humans.
2002 Apr
Effect of centrophenoxine on water-immersion restraint stress- and chemically-induced gastric ulcers in rats.
2003
Brain cholinesterases: III. Future perspectives of AD research and clinical practice.
2004
Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats.
2004 Dec
Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.
2004 Nov
Therapy of hearing disorders - conservative procedures.
2005
Modulatory effects of centrophenoxine on different regions of ageing rat brain.
2005 Oct
Evidence for centrophenoxine as a protective drug in aluminium induced behavioral and biochemical alteration in rat brain.
2006 Oct
Reversal of an aluminium induced alteration in redox status in different regions of rat brain by administration of centrophenoxine.
2006 Oct
Further evidence of centrophenoxine mediated protection in aluminium exposed rats by biochemical and light microscopy analysis.
2007 Dec
Stability-indicating electrochemical methods for the determination of meclophenoxate hydrochloride and pyritinol dihydrochloride using ion-selective membrane electrodes.
2007 Jan
Kinetic study on the degradation of meclophenoxate hydrochloride in alkaline aqueous solutions by high performance liquid chromatography.
2007 Jan
Treatment of urinary incontinence after stroke in adults.
2008 Jan 23
[Effects of piracetam and meclofenoxate on the brain NMDA and nicotinic receptors in mice with different exploratory efficacy in the cross maze test].
2008 Jan-Feb
Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
2008 Mar 27
[Effects of nicotinic cholinoreceptor ligands and nootropic drugs on the spontaneous exploratory activity in a labyrinth in mice].
2008 May-Jun
Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study.
2008 Sep
Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
2009 Nov
[Transcutaneous electrical acupoint stimulation combined with auricular acupoint sticking for treatment of primary nocturnal enuresis].
2010 May
A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma.
2010 May-Jun
Patents

Patents

Sample Use Guides

Elderly people with significant intellectual decline may chose 3 to 6 Centrophenoxine tablets (250 mg) per day taken preferably with breakfast and lunch, in order to avoid insomnia. For the non-elderly wishing to utilize the brain boosting benefits of Centrophenoxine, perhaps only 1 or 2 Centrophenoxine tablets (250 mg each) daily with breakfast or lunch.
Route of Administration: Oral
In Vitro Use Guide
The superoxide radical scavenging ability of centrophenoxine (CPH/MECLOFENOXATE) was studied in vitro using the method of pyrogallol autoxidation, cytochrome c reduction and photoxidation of o-dianisidine in salt-free assay media and in the presence of increasing NaCl or KCl concentrations. The CPH proved to be a superoxide radical scavenger in all three systems used, however, the rate constant for this reaction was rather low (1.7 X 10(2) M-1 s-1).
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:53:07 GMT 2023
Edited
by admin
on Fri Dec 15 18:53:07 GMT 2023
Record UNII
5BK3070BDY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MECLOFENOXATE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
CLOCETE
Brand Name English
BRENAL
Brand Name English
MARUCOTOL
Brand Name English
(4-CHLOROPHENOXY)ACETIC ACID 2-(DIMETHYLAMINO)ETHYL ESTER HYDROCHLORIDE
Systematic Name English
METHOXYNAL
Brand Name English
CENTROPHENOXINE HYDROCHLORIDE
Common Name English
Meclofenoxate hydrochloride [WHO-DD]
Common Name English
MECLOFENOXATE HYDROCHLORIDE [MI]
Common Name English
NSC-113619
Code English
ACETIC ACID, 2-(4-CHLOROPHENOXY)-, 2-(DIMETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE (1:1)
Common Name English
MECLOFENOXATE HYDROCHLORIDE [MART.]
Common Name English
DIMETHYLAMINOETHYL P-CHLOROPHENOXYACETATE HYDROCHLORIDE
Common Name English
CELLATIVE
Brand Name English
NSC-4268
Code English
2-(DIMETHYLAMINO)ETHYL(P-CHLORPHENOXY)ACETATE HYDROCHLORIDE
Common Name English
ACEPHEN HYDROCHLORIDE
Common Name English
MECLOFENOXATE HCL
Common Name English
PROSEROUT
Brand Name English
MECLOFENOXATE HYDROCHLORIDE [JAN]
Common Name English
MECLOFENOXANE HYDROCHLORIDE
Common Name English
LUCIDRIL
Brand Name English
HELFERGIN
Brand Name English
Code System Code Type Description
NSC
113619
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
SMS_ID
100000086164
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
MERCK INDEX
m7121
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL64545
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID8045141
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
RXCUI
236572
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
222-975-3
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
EVMPD
SUB03107MIG
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
CAS
3685-84-5
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
FDA UNII
5BK3070BDY
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
NSC
4268
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
PUBCHEM
19379
Created by admin on Fri Dec 15 18:53:07 GMT 2023 , Edited by admin on Fri Dec 15 18:53:07 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY